Last Updated: 16 Sep 2024
Executive Summary
Alkermes Plc (ALKS) is a biopharmaceutical company with a market capitalization of $4.55 billion. The company has a strong financial position with an EBITDA of $354.93 million and a profit margin of 19.2%. Alkermes' revenue has declined slightly in recent quarters, but the company remains profitable and is expected to continue to grow in the long term. The stock is currently trading at $27.83, below its 52-week high of $32.88.
Company Overview
Alkermes is a biopharmaceutical company that develops and markets pharmaceutical products for the treatment of various therapeutic areas, including central nervous system disorders, addiction, and cancer. The company's products are sold in the United States, Ireland, and internationally. Alkermes has a strong research and development pipeline, and the company is expected to launch several new products in the coming years.
Fundamental Analysis
Alkermes has a strong financial position with an EBITDA of $354.93 million and a profit margin of 19.2%. The company's revenue has declined slightly in recent quarters, but Alkermes remains profitable and is expected to continue to grow in the long term. Alkermes has a strong balance sheet with $1.2 billion in cash and equivalents and no long-term debt. The company's earnings per share (EPS) is $2.28, and the company's price-to-earnings (PE) ratio is 12.13.
Technical Analysis
The stock is currently trading at $27.83, below its 52-week high of $32.88. The stock has been trading in a range between $22.01 and $32.88 over the past year. The stock's 50-day moving average is $26.57, and the stock's 200-day moving average is $26.45. The stock's relative strength index (RSI) is 45.67, which indicates that the stock is neither overbought nor oversold.
Short Term Outlook
The stock is expected to continue to trade in a range between $22.01 and $32.88 in the short term. The stock's RSI is 45.67, which indicates that the stock is neither overbought nor oversold. The stock's 50-day moving average is $26.57, and the stock's 200-day moving average is $26.45. The stock is expected to continue to trade in a range between these two moving averages in the short term.
Long Term Outlook
The stock is expected to continue to grow in the long term. Alkermes has a strong research and development pipeline, and the company is expected to launch several new products in the coming years. The company's financial position is strong, and the company is expected to continue to generate strong cash flow. The stock is expected to continue to trade at a premium to its peers in the long term.
Analyst Recommendations
Analysts have a consensus rating of "Buy" on Alkermes Plc. The average analyst target price is $34.92, which represents a potential upside of 25.4% from the current price. Two analysts have a rating of "Strong Buy", six analysts have a rating of "Buy", five analysts have a rating of "Hold", one analyst has a rating of "Sell", and zero analysts have a rating of "Strong Sell".
